Bicycle Therapeutics plc (BCYC) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Bicycle Therapeutics (BCYC) PT Raised to $32 at Leerink Partners
October 31, 2024 1:10 PM EDTLeerink Partners analyst Jonathan Chang raised the price target on Bicycle Therapeutics (NASDAQ: BCYC) to $32.00 (from $30.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: BCYC reported 3Q24 financial results and provided a pipeline update in line with expectations. BCYC highlighted continued pipeline progress across the portfolio, including the Bicycle Toxin Conjugate (BTC) and Bicycle Radio Conjugate... More
